HRP20240583T1 - Postupci za pripremu fosforodiamidat morfolino oligomera - Google Patents
Postupci za pripremu fosforodiamidat morfolino oligomera Download PDFInfo
- Publication number
- HRP20240583T1 HRP20240583T1 HRP20240583TT HRP20240583T HRP20240583T1 HR P20240583 T1 HRP20240583 T1 HR P20240583T1 HR P20240583T T HRP20240583T T HR P20240583TT HR P20240583 T HRP20240583 T HR P20240583T HR P20240583 T1 HRP20240583 T1 HR P20240583T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- formula
- compound
- group
- carrier medium
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 12
- 150000001875 compounds Chemical class 0.000 claims 61
- -1 monomethoxytrityl Chemical group 0.000 claims 45
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 15
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 239000012351 deprotecting agent Substances 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/062—Organo-phosphoranes without P-C bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (15)
1. Postupak za pripremu oligomernog spoja formule (E):
[image]
ili njegove farmaceutski prihvatljive soli,
pri čemu se postupak sastoji od sljedećih koraka:
(a) dovođenje u kontakt spoja formule (A1):
[image]
pri čemu R1 je nosivi medij i R3 je odabran iz skupine koja sadrži tritil, monometoksitritil, dimetoksitritil i trimetoksitritil; sa sredstvom za deblokiranje da se dobije spoj formule (II):
[image]
pri čemu R1 je nosivi medij;
(b) dovođenje u kontakt spoja formule (II) sa spojem formule (A2):
[image]
pri čemu R3 je odabran iz skupine koja sadrži tritil, monometoksitritil, dimetoksitritil i trimetoksitritil;
da se dobije spoj formule (A3):
[image]
pri čemu R1 je nosivi medij, i R3 je odabran iz skupine koja sadrži tritil, monometoksitritil, dimetoksitritil i trimetoksitritil;
(c) dovođenje u kontakt spoja formule (A3) sa sredstvom za deblokiranje da se dobije spoj formule (IV):
[image]
pri čemu R1 je nosivi medij;
(d) dovođenje u kontakt spoja formule (IV) sa spojem formule (A4):
[image]
pri čemu R3 je odabran iz skupine koja sadrži tritil, monometoksitritil, dimetoksitritil i trimetoksitritil, i R4 je:
[image]
da se dobije spoj formule (A5):
[image]
pri čemu R1 je nosivi medij, R3 je odabran iz skupine koja sadrži tritil, monometoksitritil, dimetoksitritil i trimetoksitritil, i
R4 je:
[image]
;
(e) izvođenje 29 ponavljanja uzastopnih koraka:
(e1) dovođenje u kontakt proizvoda dobivenog neposredno prethodnim korakom sa sredstvom za deblokiranje; i
(e2) dovođenje u kontakt spoja nastalog u neposredno prethodnom koraku sa spojem formule (A8):
[image]
pri čemu R3 je odabran iz skupine koja sadrži tritil, monometoksitritil, dimetoksitritil i trimetoksitritil, i R4 je, ovisno o broju položaja, odabran iz skupine koja sadrži:
[image]
[image]
da se dobije spoj formule (A9):
[image]
pri čemu n je 30, R1 je nosivi medij, R3 je odabran iz skupine koja sadrži tritil, monometoksitritil, dimetoksitritil i trimetoksitritil, i R4 je, ovisno o broju položaja, odabran iz skupine koja sadrži:
[image]
[image]
i
(f) dovođenje u kontakt spoja formule (A9) sa sredstvom za deblokiranje da se dobije spoj formule (A10):
[image]
pri čemu n je 30, R1 je nosivi medij, i R4 je, ovisno o broju položaja, odabran iz skupine koja sadrži:
[image]
[image]
(g) dovođenje u kontakt spoja formule (A10) sa sredstvom za cijepanje da se dobije spoj formule (A11):
[image]
[image]
pri čemu n je 30, i R4 je, ovisno o broju položaja, odabran iz skupine koja sadrži:
[image]
[image]
i
(h) dovođenje u kontakt spoja formule (A11) sa sredstvom za uklanjanje zaštite da se dobije oligomerni spoj Formule (E).
2. Postupak prema zahtjevu 1, naznačen time što spoj formule (A4) ima formulu (A4a):
[image]
pri čemu:
R3 je odabran iz skupine koja sadrži tritil, monometoksitritil, dimetoksitritil i trimetoksitritil, i
R4 je:
[image]
3. Postupak prema zahtjevu 1 ili 2, naznačen time što spoj formule (A5) ima formulu (A5a):
[image]
pri čemu:
R1 je nosivi medij
R3 je odabran iz skupine koja sadrži tritil, monometoksitritil, dimetoksitritil i trimetoksitritil, i
R4 je:
[image]
4. Postupak prema bilo kojem od zahtjeva 1-3, naznačen time što spoj formule (A8) ima formulu (A8a):
[image]
pri čemu:
R3 je odabran iz skupine koja sadrži tritil, monometoksitritil, dimetoksitritil i trimetoksitritil, i
R4 je, ovisno o broju položaja, odabran iz skupine koja sadrži:
[image]
[image]
5. Postupak prema bilo kojem od zahtjeva 1-4, naznačen time što spoj formule (A9) ima formulu (A9a):
[image]
pri čemu:
n je 30,
R1 je nosivi medij,
R3 je odabran iz skupine koja sadrži tritil, monometoksitritil, dimetoksitritil i trimetoksitritil, i
R4 je, ovisno o broju položaja, odabran iz skupine koja sadrži:
[image]
[image]
6. Postupak prema bilo kojem od zahtjeva 1-5, naznačen time što spoj formule (A10) ima formulu (A10a):
[image]
pri čemu:
n je 30,
R1 je nosivi medij, i
R4 je, ovisno o broju položaja, odabran iz skupine koja sadrži:
[image]
[image]
7. Postupak prema bilo kojem od zahtjeva 1-6, naznačen time što spoj formule (A11) ima formulu (A11a):
[image]
pri čemu:
n je 30, i
R4 je, ovisno o broju položaja, odabran iz skupine koja sadrži:
[image]
[image]
8. Postupak prema zahtjevu 1, naznačen time što je oligomerni spoj Formule (E) oligomerni spoj Formule (XII):
[image]
ili njegova farmaceutski prihvatljiva sol.
9. Postupak prema zahtjevu 1,
naznačen time što se postupak sastoji od uzastopnih koraka:
(a) dovođenje u kontakt spoja formule (I):
[image]
pri čemu R1 je nosivi medij,
sa sredstvom za deblokiranje da se dobije spoj formule (II):
[image]
pri čemu R1 je nosivi medij;
(b) dovođenje u kontakt spoja formule (II) sa spojem (B):
[image]
da se dobije spoj formule (III):
[image]
pri čemu R1 je nosivi medij;
(c) dovođenje u kontakt spoja formule (III) sa sredstvom za deblokiranje da se dobije spoj formule (IV):
[image]
pri čemu R1 je nosivi medij;
(d) dovođenje u kontakt spoja formule (IV) sa spojem formule (C):
[image]
da se dobije spoj formule (V):
[image]
pri čemu R1 je nosivi medij;
(e) dovođenje u kontakt spoja formule (V) sa sredstvom za deblokiranje da se dobije spoj formule (VI):
[image]
pri čemu R1 je nosivi medij;
(f) dovođenje u kontakt spoja formule (VI) sa spojem formule (F):
[image]
da se dobije spoj formule (VII):
[image]
pri čemu R1 je nosivi medij;
(g) izvođenje 28 ponavljanja uzastopnih koraka:
(g1) dovođenja u kontakt proizvoda dobivenog neposredno prethodnim korakom sa sredstvom za deblokiranje; i
(g2) dovođenja u kontakt spoja nastalog u neposredno prethodnom koraku sa spojem formule (VIII):
[image]
pri čemu R2 je, ovisno o broju položaja, odabran iz skupine koja sadrži:
[image]
[image]
pri čemu, za svaku iteraciju od 1 do 28, R2 je:
[image]
da se dobije spoj formule (IX):
[image]
pri čemu R1 je nosivi medij,
pri čemu R2 je, ovisno o broju položaja, odabran iz skupine koja sadrži:
[image]
[image]
, i
pri čemu je R2 nasvakom položaju od 1 do 30 i 5’ do 3':
[image]
(h) dovođenje u kontakt spoja formule (IX) sa sredstvom za deblokiranje da se dobije spoj formule (X):
[image]
pri čemu R1 je nosivi medij,
pri čemu R2 je, ovisno o broju položaja, odabran iz skupine koja sadrži:
[image]
[image]
i
pri čemu je R2 nasvakom položaju od 1 do 30 i 5’ do 3':
[image]
(i) dovođenje u kontakt spoja formule (X) sa sredstvom za cijepanje da se dobije spoj formule (XI):
[image]
pri čemu R2 je, ovisno o broju položaja, odabran iz skupine koja sadrži:
[image]
[image]
i
pri čemu je R2 nasvakom položaju od 1 do 30 i 5’ do 3':
[image]
i
(j) dovođenje u kontakt spoja formule (XI) sa sredstvom za uklanjanje zaštite da se dobije oligomerni spoj Formule (E).
10. Spoj odabran iz skupine koja sadrži formulu (A1):
[image]
i formulu (A3):
[image]
ili njegova farmaceutski prihvatljiva sol, pri čemu:
svaki R1 je neovisno nosivi medij; i
svaki R3 je neovisno odabran iz skupine koja sadrži vodik, tritil, monometoksitritil, dimetoksitritil i trimetoksitritil.
11. Spoj formule (A5):
[image]
ili njegova farmaceutski prihvatljiva sol, naznačen time što:
R1 je nosivi medij;
R3 je odabran iz skupine koja sadrži vodik, tritil, monometoksitritil, dimetoksitritil i trimetoksitritil; i
R4 je, neovisno pri svakom pojavljivanju, odabran iz skupine koja sadrži:
[image]
[image]
[image]
12. Spoj formule (A9):
[image]
ili njegova farmaceutski prihvatljiva sol, pri čemu:
n je cijeli broj od 10 do 40;
R1 je nosivi medij;
R3 je odabran iz skupine koja sadrži vodik, tritil, monometoksitritil, dimetoksitritil i trimetoksitritil; i
R4 je, neovisno pri svakom pojavljivanju, odabran iz skupine koja sadrži:
[image]
[image]
[image]
13. Spoj prema zahtjevu 12, naznačen time što spoj formule (A9) ima formulu (A9a):
[image]
pri čemu:
n je cijeli broj od 10 do 40,
R1 je nosivi medij
R3 je odabran iz skupine koja sadrži tritil, monometoksitritil, dimetoksitritil i trimetoksitritil, i
R4 je, neovisno za svako pojavljivanje, odabran iz skupine koja sadrži:
[image]
[image]
[image]
14. Spoj prema zahtjevu 12, naznačen time što spoj formule (A9) ima formulu (IX):
[image]
ili njegova farmaceutski prihvatljiva sol, pri čemu:
R1 je nosivi medij, i
R2 je, neovisno pri svakom pojavljivanju, odabran iz skupine koja sadrži:
[image]
[image]
i
pri čemu je R2 nasvakom položaju od 1 do 30 i 5’ do 3':
[image]
15. Spoj prema zahtjevu 14, naznačen time što spoj formule (IX) ima formulu (IXa):
[image]
ili njegova farmaceutski prihvatljiva sol, pri čemu
R1 je nosivi medij, i
R2 je, neovisno pri svakom pojavljivanju, odabran iz skupine koja sadrži:
[image]
[image]
, i
pri čemu je R2 nasvakom položaju od 1 do 30 i 5’ do 3':
[image]
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662340953P | 2016-05-24 | 2016-05-24 | |
| US201662357134P | 2016-06-30 | 2016-06-30 | |
| EP17731337.6A EP3464306B1 (en) | 2016-05-24 | 2017-05-24 | Processes for preparing phosphorodiamidate morpholino oligomers |
| PCT/US2017/034284 WO2017205513A1 (en) | 2016-05-24 | 2017-05-24 | Processes for preparing phosphorodiamidate morpholino oligomers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240583T1 true HRP20240583T1 (hr) | 2024-07-19 |
Family
ID=59078166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240583TT HRP20240583T1 (hr) | 2016-05-24 | 2017-05-24 | Postupci za pripremu fosforodiamidat morfolino oligomera |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10961262B2 (hr) |
| EP (2) | EP3464306B1 (hr) |
| JP (1) | JP6987081B2 (hr) |
| KR (1) | KR102504759B1 (hr) |
| CN (1) | CN109311920B (hr) |
| AU (1) | AU2017271524B2 (hr) |
| BR (1) | BR112018074270B1 (hr) |
| CA (1) | CA3024182A1 (hr) |
| CO (1) | CO2018013827A2 (hr) |
| DK (1) | DK3464306T3 (hr) |
| FI (1) | FI3464306T3 (hr) |
| HR (1) | HRP20240583T1 (hr) |
| HU (1) | HUE066393T2 (hr) |
| IL (1) | IL263033B2 (hr) |
| LT (1) | LT3464306T (hr) |
| MA (1) | MA45155A (hr) |
| MD (1) | MD3464306T2 (hr) |
| MX (1) | MX2018014162A (hr) |
| PL (1) | PL3464306T3 (hr) |
| PT (1) | PT3464306T (hr) |
| RS (1) | RS65504B1 (hr) |
| SA (1) | SA518400462B1 (hr) |
| SG (1) | SG11201809499UA (hr) |
| SI (1) | SI3464306T1 (hr) |
| TW (1) | TWI737736B (hr) |
| WO (1) | WO2017205513A1 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| US11472824B2 (en) | 2016-05-24 | 2022-10-18 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| CA3024182A1 (en) * | 2016-05-24 | 2017-11-30 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| SG11201809502YA (en) * | 2016-05-24 | 2018-12-28 | Sarepta Therapeutics Inc | Processes for preparing phosphorodiamidate morpholino oligomers |
| EP3564248A1 (en) * | 2016-05-24 | 2019-11-06 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| MA45362A (fr) * | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics Inc | Procédés de préparation d'oligomères morpholino de phosphorodiamidate |
| JP7022078B2 (ja) * | 2016-06-30 | 2022-02-17 | サレプタ セラピューティクス， インコーポレイテッド | ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス |
| JP7218361B2 (ja) * | 2017-09-25 | 2023-02-06 | サレプタ セラピューティクス， インコーポレイテッド | 高速流動合成を介してホスホロジアミデートモルホリノオリゴマーを調製するための方法 |
| EP3829595A4 (en) | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF DYSTROPHINOPATHIES |
| CN109704980B (zh) * | 2019-02-16 | 2022-05-13 | 安徽大学 | 一种(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的制备方法 |
| EP4123023A4 (en) * | 2020-03-16 | 2024-07-17 | Univ Nat Corp Tokyo Medical & Dental | HETERONUCLEIC ACID WITH MORPHOLINONUCLEIC ACID |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| CN118201640A (zh) * | 2021-11-01 | 2024-06-14 | 达因疗法公司 | 用于治疗肌养蛋白病的肌肉靶向复合物 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| EP0639582B1 (en) | 1985-03-15 | 1998-09-16 | Antivirals Inc. | Polynucleotide assay reagent and method |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| EP0433345B1 (en) | 1988-09-01 | 1994-04-20 | Forskningscenter Riso | Peptide synthesis method and solid support for use in the method |
| AU694157B2 (en) | 1993-12-29 | 1998-07-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine adenosine antagonists |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US7572582B2 (en) | 1997-09-12 | 2009-08-11 | Exiqon A/S | Oligonucleotide analogues |
| US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
| KR100782896B1 (ko) | 1999-05-04 | 2007-12-06 | 엑시콘 에이/에스 | Ｌ-리보-ｌｎａ 유사체 |
| JP2003533986A (ja) | 2000-05-04 | 2003-11-18 | エイブイアイ バイオファーマ， インコーポレイテッド | スプライス領域アンチセンス組成物および方法 |
| AU2002334307A1 (en) | 2001-09-04 | 2003-03-18 | Exiqon A/S | Novel lna compositions and uses thereof |
| US7569575B2 (en) | 2002-05-08 | 2009-08-04 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
| EP1563070A4 (en) | 2002-11-05 | 2008-05-28 | Isis Pharmaceuticals Inc | 2'-SUBSTITUTED OLIGOMER COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS |
| US7759513B2 (en) | 2003-02-21 | 2010-07-20 | Nigu Chemie Gmbh | Photolabile protective groups for improved processes to prepare oligonucleotide arrays |
| EP3808845A1 (en) | 2004-06-28 | 2021-04-21 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| US9371348B2 (en) | 2006-11-27 | 2016-06-21 | The Trustees Of The University Of Pennsylvania | Photocleavable oligonucleotide and uses thereof |
| US8299206B2 (en) | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| WO2009064471A1 (en) | 2007-11-15 | 2009-05-22 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| ES2573981T3 (es) | 2009-04-10 | 2016-06-13 | Association Institut De Myologie | Oligonucleótidos antisentido de triciclo-ADN, composiciones, y métodos para el tratamiento de enfermedades |
| KR20230137491A (ko) | 2009-11-12 | 2023-10-04 | 더 유니버시티 오브 웨스턴 오스트레일리아 | 안티센스 분자 및 이를 이용한 질환 치료방법 |
| KR102095478B1 (ko) * | 2010-05-28 | 2020-04-01 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| TWI463423B (zh) * | 2010-05-28 | 2014-12-01 | Poynt Corp | 用以針對基於三維形狀之廣告系統使用位置資訊的方法 |
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| ES2607603T3 (es) | 2010-09-30 | 2017-04-03 | Nippon Shinyaku Co., Ltd. | Derivado de ácido morfolino nucleico |
| EP2672977A1 (en) * | 2011-02-08 | 2013-12-18 | The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System | Antisense oligonucleotides |
| US9920084B2 (en) | 2011-08-23 | 2018-03-20 | The Royal Institution For The Advancement Of Learning/Mcgill University | Ionic tags for synthesis of oligoribonucleotides |
| PT2581448E (pt) | 2011-10-13 | 2015-05-21 | Institut National De La Santé Et De La Rech Médicale (Inserm) | Dna triciclo-fosforotioato |
| BR112014011875B1 (pt) | 2011-11-18 | 2022-01-04 | Sarepta Therapeutics, Inc | Oligonucleotídeos funcionalmente modificados e subunidades dos mesmos |
| US9944926B2 (en) | 2011-11-30 | 2018-04-17 | Sarepta Therapeutics, Inc. | Induced exon inclusion in spinal muscle atrophy |
| ES2748868T3 (es) * | 2011-12-28 | 2020-03-18 | Nippon Shinyaku Co Ltd | Acido nucleico antisentido |
| EP3287531B1 (en) | 2012-02-28 | 2019-06-19 | Agilent Technologies, Inc. | Method for attaching a counter sequence to a nucleic acid sample |
| CN102702265A (zh) * | 2012-05-14 | 2012-10-03 | 天津特安化学科技有限公司 | 一种固相合成磷酰二胺吗啉代寡核苷酸及方法 |
| AU2014236160A1 (en) * | 2013-03-14 | 2015-10-01 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| US20140329881A1 (en) * | 2013-03-14 | 2014-11-06 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| EP2968991A2 (en) * | 2013-03-15 | 2016-01-20 | Sarepta Therapeutics, Inc. | Improved compositions for treating muscular dystrophy |
| US8999152B2 (en) * | 2013-03-15 | 2015-04-07 | Uop Llc | Process and apparatus for recovering and blending hydroprocessed hydrocarbons and composition |
| CN105228999B (zh) * | 2013-05-24 | 2021-03-02 | 味之素株式会社 | 吗啉代寡核苷酸的制备方法 |
| US11472824B2 (en) | 2016-05-24 | 2022-10-18 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| MA45362A (fr) * | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics Inc | Procédés de préparation d'oligomères morpholino de phosphorodiamidate |
| EP3564248A1 (en) * | 2016-05-24 | 2019-11-06 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| CA3024182A1 (en) | 2016-05-24 | 2017-11-30 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| MX2018014123A (es) | 2016-05-24 | 2019-04-29 | Sarepta Therapeutics Inc | Procesos para preparar oligomeros de morfolino fosforodiamidato. |
| US10888578B2 (en) | 2016-12-19 | 2021-01-12 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
-
2017
- 2017-05-24 CA CA3024182A patent/CA3024182A1/en active Pending
- 2017-05-24 DK DK17731337.6T patent/DK3464306T3/da active
- 2017-05-24 MA MA045155A patent/MA45155A/fr unknown
- 2017-05-24 US US16/302,443 patent/US10961262B2/en active Active
- 2017-05-24 CN CN201780030642.8A patent/CN109311920B/zh active Active
- 2017-05-24 EP EP17731337.6A patent/EP3464306B1/en active Active
- 2017-05-24 RS RS20240522A patent/RS65504B1/sr unknown
- 2017-05-24 MX MX2018014162A patent/MX2018014162A/es unknown
- 2017-05-24 FI FIEP17731337.6T patent/FI3464306T3/fi active
- 2017-05-24 EP EP24161437.9A patent/EP4406600A3/en active Pending
- 2017-05-24 PL PL17731337.6T patent/PL3464306T3/pl unknown
- 2017-05-24 HR HRP20240583TT patent/HRP20240583T1/hr unknown
- 2017-05-24 MD MDE20190424T patent/MD3464306T2/ro unknown
- 2017-05-24 LT LTEPPCT/US2017/034284T patent/LT3464306T/lt unknown
- 2017-05-24 SG SG11201809499UA patent/SG11201809499UA/en unknown
- 2017-05-24 JP JP2018560662A patent/JP6987081B2/ja active Active
- 2017-05-24 SI SI201731516T patent/SI3464306T1/sl unknown
- 2017-05-24 TW TW106117191A patent/TWI737736B/zh active
- 2017-05-24 KR KR1020187036634A patent/KR102504759B1/ko active IP Right Grant
- 2017-05-24 BR BR112018074270-8A patent/BR112018074270B1/pt active IP Right Grant
- 2017-05-24 WO PCT/US2017/034284 patent/WO2017205513A1/en active Application Filing
- 2017-05-24 AU AU2017271524A patent/AU2017271524B2/en active Active
- 2017-05-24 HU HUE17731337A patent/HUE066393T2/hu unknown
- 2017-05-24 PT PT177313376T patent/PT3464306T/pt unknown
-
2018
- 2018-11-15 IL IL263033A patent/IL263033B2/en unknown
- 2018-11-19 SA SA518400462A patent/SA518400462B1/ar unknown
- 2018-12-19 CO CONC2018/0013827A patent/CO2018013827A2/es unknown
-
2021
- 2021-02-08 US US17/169,611 patent/US20220340605A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240583T1 (hr) | Postupci za pripremu fosforodiamidat morfolino oligomera | |
| JP6188757B2 (ja) | 均一系触媒作用を利用したアルコール・アミノ化による一級アミンの製造方法 | |
| CN107208304B (zh) | 取向性电磁钢板的制造方法 | |
| DE60316728D1 (de) | Phosphonium- und imidazoliumsalze und verfahren zu deren herstellung | |
| AR060545A1 (es) | Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas | |
| JP2009500319A5 (hr) | ||
| AR044694A1 (es) | Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo | |
| IE32801L (en) | Separating diastereoisomers | |
| KR920004370A (ko) | 탁솔의 수용성 유도체 | |
| CA2515669A1 (en) | Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes | |
| BR112019022269A2 (pt) | processo para a preparação de etanol deuterado a partir de d2 | |
| JPWO2020004649A5 (hr) | ||
| RU2017142725A (ru) | Способ получения производных азотистого иприта | |
| GB1326473A (en) | Process for purifying alpha-l-aspartyl-l-phenylalanine methyl ester and intermediates in said process | |
| EE05064B1 (et) | Meetod tuntud tetrasooli derivaadi snteesiks | |
| ES2197818A1 (es) | 2,7,12,17 alquenil, aril y heteroaril derivados del 3,6,13,16-tetraazaporficeno, y procedimiento, compuesto intermedio y utilizaciones correspondientes. | |
| AR126196A1 (es) | Proceso para preparar inhibidores de egfr | |
| TW206224B (hr) | ||
| TW200736835A (en) | Positive resist composition and method for forming resist pattern | |
| KR20060123066A (ko) | 베타-아미노케톤의 비대칭 수소화 방법 | |
| DE60329723D1 (de) | Anlage zur kontinuierlichen herstellung eines geschweissten metalldrahtgitters | |
| AR118674A1 (es) | Proceso para la producción de derivados de 2-[2-(fenil)etilamino]alcanamida sustituidos | |
| UY39821A (es) | Un proceso para la preparacion de un producto intermedio de l-glufosinato | |
| CO5550441A2 (es) | Nuevos derivados de ziprasidona, procedimientos para prepararlos y composiciones que los contienen | |
| US2348417A (en) | Arsanilic acid azo sulphonamide compound |